This study is investigating an experimental drug called mibavademab for adult women with Functional Hypothalamic Amenorrhea (FHA). FHA is a condition where your brain doesn't send the right signals to your ovaries, causing your periods to stop. The main goal is to see how well mibavademab helps your body produce the hormones needed for ovulation and reproduction, and to check its safety. You might be able to join if you are a woman between 18 and 40 years old, have a diagnosis of FHA, and haven't had a period for at least 3 months. The study is also looking at how mibavademab might affect bone health and what side effects it may cause. The study plans to enroll 34 participants, and its current status is unclear.

Study design

This interventional study is testing mibavademab against a placebo. It plans to enroll 34 adult women.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures changes in a hormone called estradiol from the beginning of the study up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.